SANTA MONICA, Calif. – GoodRx has announced the availability of Repatha (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price.
“In a healthcare system where affordability too often dictates access, GoodRx remains focused on delivering meaningful savings to patients at scale,” said Laura Jensen, Chief Commercial Officer and President of Pharma Solutions at GoodRx. “GoodRx is serving as the digital storefront to make Repatha more accessible for patients, leveraging our extensive retail pharmacy network to ensure it’s available where they already fill their prescriptions. This combination of meaningful savings and broad distribution helps break down barriers so patients can start and stay on the therapies that matter most for their health.”
By making Repatha accessible at a lower cash price than was previously available at retail, GoodRx and Amgen are helping patients bypass traditional insurance hurdles, such as restrictive formularies and high deductibles, that often delay or prevent treatment. GoodRx is pioneering direct-to-consumer solutions that give brands a trusted, scalable channel to deliver real savings directly to patients.
The $239 cash price for Repatha is available today at more than 70,000 pharmacies nationwide through GoodRx.
Learn more at GoodRx.com/Repatha
